Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A promising Alzheimer's therapy keeps getting better with time. Diranersen, an antisense oligonucleotide that targets tau, continued to slow cognitive and functional decline at 96 weeks in the open-label extension of the phase II CELIA trial — with treatment effects growing stronger between 18 months and 2 years. The 60-mg twice-yearly dose showed the most impressive results, with a clinically meaningful 1.09-point improvement on the CDR-SB scale.
A promising Alzheimer's therapy keeps getting better with time. Diranersen, an investigational antisense oligonucleotide that lowers tau protein levels, continued to slow cognitive and functional decline at 96 weeks in the open-label extension of the phase II CELIA trial. Presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, the data showed that treatment effects grew stronger between 18 months and 2 years — a trend researchers described as "remarkable."
The 60-mg twice-yearly dose performed best, delivering a 1.09-point treatment difference on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 96 weeks — a clinically meaningful margin. Safety remained consistent with earlier data, with most adverse events being mild to moderate.
By the Numbers:
Why it matters: Diranersen is the first drug from a randomized trial to show that lowering tau may slow cognitive decline — and notably, it does so without affecting amyloid. That makes it a strong candidate for combination therapy alongside existing anti-amyloid treatments, potentially targeting Alzheimer's disease from multiple angles.